Peptides targeting angiogenesis related growth factor receptors

Current Pharmaceutical Design

Volumn 15, Issue 21, 2009, Pages 2414-2429

  D'Andrea, Luca D ^a   Del Gatto, Annarita ^a   De Rosa, Lucia ^a   Romanelli, Alessandra ^b   Pedone, Carlo ^b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Angiogenesis; FGF; Growth factor; PDGF; Peptide; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BECAPLERMIN; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1 ANTAGONIST; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 2 ANTAGONIST; FIBROBLAST GROWTH FACTOR 5 ANTAGONIST; FIBROBLAST GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN INHIBITOR; PROTEOHEPARAN SULFATE; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HAIR LOSS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69249113838     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682235     Document Type: Review

References (240)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
3. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-78.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
7. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
8. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
9. Bouis D, Kusumanto Y, Meijer C, Mulder NH, Hospers GA. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res 2006; 53: 89-103.
10. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
11. Rajkumar T. Growth factoprs and growth factor receptors in cancer. Current Science 2001; 81: 535-241.
12. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7: 971-94.
13. Okarvi SM. Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004; 24: 357-97.
14. Ruegg C, Hasmim M, Lejeune FJ, Alghisi GC. Antiangiogenic peptides and proteins: From experimental tools to clinical drugs. Biochim Biophys Acta 2006; 1765: 155-77.
15. D'Andrea LD, Del Gatto A, Pedone C, Benedetti E. Peptide-based molecules in angiogenesis. Chem Biol Drug Des 2006; 67: 115-26.
16. Dings RP, Nesmelova I, Griffioen AW, Mayo KH. Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis 2003; 6: 83-91.
17. Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 2007; 13: 2074-86.
18. Bouma-ter Steege JC, Mayo KH, Griffioen AW. Angiostatic proteins and peptides. Crit Rev Eukaryot Gene Expr 2001; 11: 319-34.
19. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88.
20. Abraham JA, Whang JL, Tumolo A, Mergia A, Fiddes JC. Human basic fibroblast growth factor: Nucleotide sequence, genomic organization, and expression in mammalian cells. Cold Spring Harb Symp Quant Biol 1986; 51 Pt 1: 657-68.
21. Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA, et al. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986; 233: 545-8.
22. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-97.
23. Ago H, Kitagawa Y, Fujishima A, Matsuura Y, Katsube Y. Crystal structure of basic fibroblast growth factor at 1.6 A resolution. J Biochem 1991; 110: 360-3.
24. Eriksson AE, Cousens LS, Weaver LH, Matthews BW. Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci USA 1991; 88: 3441-5.
25. Zhu X, Komiya H, Chirino A, Faham S, Fox GM, Arakawa T, et al. Three-dimensional structures of acidic and basic fibroblast growth factors. Science 1991; 251: 90-3.
26. Zhang JD, Cousens LS, Barr PJ, Sprang SR. Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta. Proc Natl Acad Sci USA 1991; 88: 3446-50.
27. Reuss B, von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res 2003; 313: 139-57.
28. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2: reviews3005.1-3005.12.
29. Klagsbrun M, Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 1991; 67: 229-31.
30. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 107: 743-51.
31. Turnbull JE, Gallagher JT. Heparan sulphate: Functional role as a modulator of fibroblast growth factor activity. Biochem Soc Trans 1993; 21: 477-82.
32. David G. Integral membrane heparan sulfate proteoglycans. Faseb J 1993; 7: 1023-30.
33. Ornitz DM, Leder P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J Biol Chem 1992; 267: 16305-11.
34. Mansukhani A, Dell'Era P, Moscatelli D, Kornbluth S, Hanafusa H, Basilico C. Characterization of the murine BEK fibroblast growth factor (FGF) receptor: Activation by three members of the FGF family and requirement for heparin. Proc Natl Acad Sci USA 1992; 89: 3305-9.
35. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841-8.
36. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 1705-8.
37. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007; 75: 831-42.
38. Lee PL, Johnson DE, Cousens LS, Fried VA, Williams LT. Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor. Science 1989; 245: 57-60.
39. Reid HH, Wilks AF, Bernard O. Two forms of the basic fibroblast growth factor receptor-like mRNA are expressed in the developing mouse brain. Proc Natl Acad Sci USA 1990; 87: 1596-600.
40. Safran A, Avivi A, Orr-Urtereger A, Neufeld G, Lonai P, Givol D, et al. The murine flg gene encodes a receptor for fibroblast growth factor. Oncogene 1990; 5: 635-43.
41. Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M, et al. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J 1990; 9: 2685-92.
42. Keegan K, Johnson DE, Williams LT, Hayman MJ. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci USA 1991; 88: 1095-9.
43. Partanen J, Makela TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L, et al. FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J 1991; 10: 1347-54.
44. Stark KL, McMahon JA, McMahon AP. FGFR-4, a new member of the fibroblast growth factor receptor family, expressed in the definitive endoderm and skeletal muscle lineages of the mouse. Development 1991; 113: 641-51.
45. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281: 15694-700.
46. Stauber DJ, DiGabriele AD, Hendrickson WA. Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci USA 2000; 97: 49-54.
47. Venkataraman G, Shriver Z, Davis JC, Sasisekharan R. Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans. Proc Natl Acad Sci USA 1999; 96: 1892-7.
48. Zhan X, Plourde C, Hu X, Friesel R, Maciag T. Association of fibroblast growth factor receptor-1 with c-Src correlates with association between c-Src and cortactin. J Biol Chem 1994; 269: 20221-4.
49. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201-7.
50. Cross MJ, Hodgkin MN, Roberts S, Landgren E, Wakelam MJ, Claesson-Welsh L. Tyrosine 766 in the fibroblast growth factor receptor 1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A(2), phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells. J Cell Sci 2000; 113 (Pt 4): 643-51.
51. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
52. Raffioni S, Thomas D, Foehr ED, Thompson LM, Bradshaw RA. Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells. Proc Natl Acad Sci USA 1999; 96: 7178-83.
53. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-78.
54. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 2007; 13: 2025-44.
55. Rusnati M, Presta M. Targeting fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Antiangiogenic Cancer Ther 2008: 189-223.
56. Mignatti P, Rifkin DB. Nonenzymatic interactions between proteinases and the cell surface: Novel roles in normal and malignant cell physiology. Adv Cancer Res 2000; 78: 103-57.
57. Stokes CL, Rupnick MA, Williams SK, Lauffenburger DA. Chemotaxis of human microvessel endothelial cells in response to acidic fibroblast growth factor. Lab Invest 1990; 63: 657-68.
58. Terranova VP, DiFlorio R, Lyall RM, Hic S, Friesel R, Maciag T. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 1985; 101: 2330-4.
59. Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene 2001; 20: 2791-804.
60. Gillis P, Savla U, Volpert OV, Jimenez B, Waters CM, Panos RJ, et al. Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. J Cell Sci 1999; 112 (Pt 12): 2049-57.
61. Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 1993; 4: 973-82.
62. Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. J Cell Sci 1999; 112 (Pt 4): 569-78.
63. Sepp NT, Li LJ, Lee KH, Brown EJ, Caughman SW, Lawley TJ, et al. Basic fibroblast growth factor increases expression of the alpha v beta 3 integrin complex on human microvascular endothelial cells. J Invest Dermatol 1994; 103: 295-9.
64. Underwood PA, Bean PA, Gamble JR. Rate of endothelial expansion is controlled by cell:cEll adhesion. Int J Biochem Cell Biol 2002; 34: 55-69.
65. Zhou L, Dosanjh A, Chen H, Karasek M. Divergent effects of extracellular oxygen on the growth, morphology, and function of human skin microvascular endothelial cells. J Cell Physiol 2000; 182: 134-40.
66. Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Molinari-Tosatti MP, et al. Basic fibroblast growth factor overexpression in endothelial cells: An autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996; 7: 147-60.
67. Armstrong E, Vainikka S, Partanen J, Korhonen J, Alitalo R. Expression of fibroblast growth factor receptors in human leukemia cells. Cancer Res 1992; 52: 2004-7.
68. Allouche M, Bayard F, Clamens S, Fillola G, Sie P, Amalric F. Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia 1995; 9: 77-86.
69. Katoh O, Hattori Y, Sato T, Kimura A, Kuramoto A, Sugimura T, et al. Expression of the heparin-binding growth factor receptor genes in human megakaryocytic leukemia cells. Biochem Biophys Res Commun 1992; 183: 83-92.
70. Liuzzo JP, Moscatelli D. Human leukemia cell lines bind basic fibroblast growth factor (FGF) on FGF receptors and heparan sulfates: downmodulation of FGF receptors by phorbol ester. Blood 1996; 87: 245-55.
71. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 115-65.
72. Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 2000; 34: 89-110.
73. Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther 2001; 299: 1073-85.
74. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-73.
75. Lindahl U, Lidholt K, Spillmann D, Kjellen L. More to "heparin" than anticoagulation. Thromb Res 1994; 75: 1-32
76. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J Clin Invest 2001; 108: 349-55.
77. Rusnati M, Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int J Clin Lab Res 1996; 26: 15-23.
78. Ribatti D, Leali D, Vacca A, Giuliani R, Gualandris A, Roncali L, et al. In vivo angiogenic activity of urokinase: Role of endogenous fibroblast growth factor-2. J Cell Sci 1999; 112 (Pt 23): 4213-21.
79. Presta M, Maier JA, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol 1989; 140: 68-74.
80. Simons M, Horowitz A. Syndecan-4-mediated signalling. Cell Signal 2001; 13: 855-62.
81. Rusnati M, Urbinati C, Presta M. Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: Role of the low affinity heparin-like bFGF receptors. J Cell Physiol 1993; 154: 152-61.
82. Hsia E, Richardson TP, Nugent MA. Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling. J Cell Biochem 2003; 88: 1214-25
83. Gajdusek CM, Carbon S. Injury-induced release of basic fibroblast growth factor from bovine aortic endothelium. J Cell Physiol 1989; 139: 570-9.
84. Gloe T, Sohn HY, Meininger GA, Pohl U. Shear stress-induced release of basic fibroblast growth factor from endothelial cells is mediated by matrix interaction via integrin alpha(v)beta3. J Biol Chem 2002; 277: 23453-8.
85. Hartnett ME, Garcia CM, D'Amore PA. Release of bFGF, an endothelial cell survival factor, by osmotic shock. Invest Ophthalmol Vis Sci 1999; 40: 2945-51.
86. Pugh CW. Oxygen sensing in cancer. Ann Med 2003; 35: 380-90.
87. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995; 92: 4606-10.
88. Li J, Shworak NW, Simons M. Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. J Cell Sci 2002; 115: 1951-9.
89. Ornitz DM. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 2000; 22: 108-12.
90. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 2000; 101: 413-24.
91. Moy FJ, Seddon AP, Bohlen P, Powers R. High-resolution solution structure of basic fibroblast growth factor determined by multidimensional heteronuclear magnetic resonance spectroscopy. Biochemistry 1996; 35: 13552-61.
92. Li LY, Safran M, Aviezer D, Bohlen P, Seddon AP, Yayon A. Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry 1994; 33: 10999-1007.
93. Blaber M, DiSalvo J, Thomas KA. X-ray crystal structure of human acidic fibroblast growth factor. Biochemistry 1996; 35: 2086-94.
94. Eriksson AE, Cousens LS, Matthews BW. Refinement of the structure of human basic fibroblast growth factor at 1.6 A resolution and analysis of presumed heparin binding sites by selenate substitution. Protein Sci 1993; 2: 1274-84.
95. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and interactions with basic fibroblast growth factor. Science 1996; 271: 1116-20.
96. DiGabriele AD, Lax I, Chen DI, Svahn CM, Jaye M, Schlessinger J, et al. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 1998; 393: 812-7.
97. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999; 98: 641-50
98. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992; 12: 240-7.
99. Sudhalter J, Folkman J, Svahn CM, Bergendal K, D'Amore PA. Importance of size, sulfation, and anticoagulant activity in the potentiation of acidic fibroblast growth factor by heparin. J Biol Chem 1989; 264: 6892-7.
100. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000; 6: 743-50.
101. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000; 407: 1029-34.
102. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993; 259: 1918-21.
103. Schubert D, Ling N, Baird A. Multiple influences of a heparin-binding growth factor on neuronal development. J Cell Biol 1987; 104: 635-43
104. Baird A, Schubert D, Ling N, Guillemin R. Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc Natl Acad Sci USA 1988; 85: 2324-8.
105. Ray J, Baird A, Gage FH. A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells. Proc Natl Acad Sci USA 1997; 94: 7047-52.
106. Williams EJ, Williams G, Howell FV, Skaper SD, Walsh FS, Doherty P. Identification of an N-cadherin motif that can interact with the fibroblast growth factor receptor and is required for axonal growth. J Biol Chem 2001; 276: 43879-86.
107. Ito C, Saitoh Y, Fujita Y, Yamazaki Y, Imamura T, Oka S, et al. Decapeptide with fibroblast growth factor (FGF)-5 partial sequence inhibits hair growth suppressing activity of FGF-5. J Cell Physiol 2003; 197: 272-83.
108. Yayon A, Aviezer D, Safran M, Gross JL, Heldman Y, Cabilly S, et al. Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. Proc Natl Acad Sci USA 1993; 90: 10643-7.
109. Terada T, Mizobata M, Kawakami S, Yabe Y, Yamashita F, Hashida M. Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. J Drug Target 2006; 14: 536-45.
110. Maruta F, Parker AL, Fisher KD, Hallissey MT, Ismail T, Rowlands DC, et al. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther 2002; 9: 543-52.
111. Cosic I, Drummond AE, Underwood JR, Hearn MT. In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide. Mol Cell Biochem 1994; 130: 1-9.
112. McConnell SJ, Thon VJ, Spinella DG. Isolation of fibroblast growth factor receptor binding sequences using evolved phage display libraries. Comb Chem High Throughput Screen 1999; 2: 155-63.
113. Fan H, Duan Y, Zhou H, Li W, Li F, Guo L, et al. Selection of peptide ligands binding to fibroblast growth factor receptor 1. IUBMB Life 2002; 54: 67-72.
114. Oyama S, Jr., Miranda MT, Toma IN, Viviani W, Gambarini AG. Mitogenic activity of peptides related to the sequence of human fibroblast growth factor-1. Biochem Mol Biol Int 1996; 39: 1237-44.
115. Kiyota S, Franzoni L, Nicastro G, Benedetti A, Oyama S, Jr., Viviani W, et al. Introduction of a chemical constraint in a short peptide derived from human acidic fibroblast growth factor elicits mitogenic structural determinants. J Med Chem 2003; 46: 2325-33.
116. Tzeng SF, Deibler GE, DeVries GH. Myelin basic protein and myelin basic protein peptides induce the proliferation of Schwann cells via ganglioside GM1 and the FGF receptor. Neurochem Res 1999; 24: 255-60
117. Li S, Christensen C, Kiselyov VV, Kohler LB, Bock E, Berezin V. Fibroblast growth factor-derived peptides: Functional agonists of the fibroblast growth factor receptor. J Neurochem 2008; 104: 667-82.
118. Anderson AA, Kendal CE, Garcia-Maya M, Kenny AV, Morris-Triggs SA, Wu T, et al. A peptide from the first fibronectin domain of NCAM acts as an inverse agonist and stimulates FGF receptor activation, neurite outgrowth and survival. J Neurochem 2005; 95: 570-83.
119. Ballinger MD, Shyamala V, Forrest LD, Deuter-Reinhard M, Doyle LV, Wang JX, et al. Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Nat Biotechnol 1999; 17: 1199-204
120. Kiselyov VV, Skladchikova G, Hinsby AM, Jensen PH, Kulahin N, Soroka V, et al. Structural basis for a direct interaction between FGFR1 and NCAM and evidence for a regulatory role of ATP. Structure 2003; 11: 691-701.
121. Neiiendam JL, Kohler LB, Christensen C, Li S, Pedersen MV, Ditlevsen DK, et al. An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. J Neurochem 2004; 91: 920-35.
122. Lin X, Takahashi K, Campion SL, Liu Y, Gustavsen GG, Pena LA, et al. Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo. Int J Mol Med 2006; 17: 833-9.
123. Lin X, Pena LA, Zamora PO, Campion SL, Takahashi K. Augmentation of demineralized bone matrix (DBM) mineralization by a synthetic growth factor mimetic. J Orthop Res 2006; 24: 2051-8.
124. Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 1974; 71: 1207-10.
125. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem 1994; 269: 32023-6.
126. Kazlauskas A. Receptor tyrosine kinases and their targets. Curr Opin Genet Dev 1994; 4: 5-14.
127. Fredriksson L, Li H, Eriksson U. The PDGF family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004; 15: 197-204.
128. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-316.
129. Fredriksson L, Li H, Fieber C, Li X, Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. Embo J 2004; 23: 3793-802.
130. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993; 62: 453-81.
131. Matsui T, Heidaran M, Miki T, Popescu N, La Rochelle W, Kraus M, et al. Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 1989; 243: 800-4.
132. Kelly JD, Haldeman BA, Grant FJ, Murray MJ, Seifert RA, Bowen-Pope DF, et al. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J Biol Chem 1991; 266: 8987-92.
133. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-312.
134. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 2002; 398: 284-90.
135. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81: 1241-57.
136. Sundberg C, Branting M, Gerdin B, Rubin K. Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cells. Am J Pathol 1997; 151: 479-92.
137. Yi ES, Lee H, Yin S, Piguet P, Sarosi I, Kaufmann S, et al. Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am J Pathol 1996; 149: 539-48.
138. Rutherford C, Martin W, Carrier M, Anggard EE, Ferns GA. Endogenously elicited antibodies to platelet derived growth factor- BB and platelet cytosolic protein inhibit aortic lesion development in the cholesterol-fed rabbit. Int J Exp Pathol 1997; 78: 21-32.
139. Abboud HE. Role of platelet-derived growth factor in renal injury. Annu Rev Physiol 1995; 57: 297-309.
140. Gesualdo L, Di Paolo S, Milani S, Pinzani M, Grappone C, Ranieri E, et al. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J Clin Invest 1994; 94: 50-8.
141. Gesualdo L, Pinzani M, Floriano JJ, Hassan MO, Nagy NU, Schena FP, et al. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab Invest 1991; 65: 160-7.
142. Yamamoto M, Toya Y, Jensen RA, Ishikawa Y. Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res 1999; 247: 380-8.
143. Engstrom U, Engstrom A, Ernlund A, Westermark B, Heldin CH. Identification of a peptide antagonist for platelet-derived growth factor. J Biol Chem 1992; 267: 16581-7.
144. Brennand DM, Dennehy U, Ellis V, Scully MF, Tripathi P, Kakkar VV, et al. Identification of a cyclic peptide inhibitor of platelet-derived growth factor-BB receptor-binding and mitogen-induced DNA synthesis in human fibroblasts. FEBS Lett 1997; 413: 70-4.
145. Brennand DM, Scully MF, Kakkar VV, Patel G. A cyclic peptide analogue of loop III of PDGF-BB causes apoptosis in human fibroblasts. FEBS Lett 1997; 419: 166-70.
146. Chiara F, Bishayee S, Heldin CH, Demoulin JB. Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase by its C-terminal tail. J Biol Chem 2004; 279: 19732-8.
147. Lin X, Takahashi K, Liu Y, Derrien A, Zamora PO. A synthetic, bioactive PDGF mimetic with binding to both alpha-PDGF and beta-PDGF receptors. Growth Factors 2007; 25: 87-93.
148. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the Induction of Pathological Angiogenesis. Annu Rev Pathol 2007; 2: 251-75.
149. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-26.
150. Roth D, Piekarek M, Paulsson M, Christ H, Bloch W, Krieg T, et al. Plasmin modulates vascular endothelial growth factor-Amediated angiogenesis during wound repair. Am J Pathol 2006; 168: 670-84.
151. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822-35.
152. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991; 88: 9267-71.
153. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): Novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 2002; 979: 80-93.
154. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-75.
155. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-40.
156. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580: 2879-87.
157. Iyer S, Acharya KR. Role of placenta growth factor in cardiovascular health. Trends Cardiovasc Med 2002; 12: 128-34.
158. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-83.
159. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993; 9: 259-68.
160. Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993; 8: 925-31.
161. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
162. Ferrara N. VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11: 617-24.
163. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
164. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28: 488-94.
165. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203-12.
166. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.
167. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 2001: RE21.
168. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349-54.
169. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002; 8: 841-9.
170. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-43.
171. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-9.
172. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58.
173. Oliver G, Alitalo K. The lymphatic vasculature: Recent progress and paradigms. Annu Rev Cell Dev Biol 2005; 21: 457-83.
174. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438: 946-53.
175. Achen MG, Williams RA, Minekus MP, Thornton GE, Stenvers K, Rogers PA, et al. Localization of vascular endothelial growth factor D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 2001; 193: 147-54.
176. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154: 1381-90.
177. Pellet-Many C, Frankel P, Jia H, Zachary I. Neuropilins: Structure, function and role in disease. Biochem J 2008; 411: 211-26.
178. Geretti E, Shimizu A, Klagsbrun M. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 2008; 11: 31-9.
179. Muller YA, Christinger HW, Keyt BA, de Vos AM. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure 1997; 5: 1325-38.
180. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 1997; 94: 7192-7.
181. Pan B, Li B, Russell SJ, Tom JY, Cochran AG, Fairbrother WJ. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor. J Mol Biol 2002; 316: 769-87.
182. Wiesmann C, Christinger HW, Cochran AG, Cunningham BC, Fairbrother WJ, Keenan CJ, et al. Crystal structure of the complex between VEGF and a receptor-blocking peptide. Biochemistry 1998; 37: 17765-72.
183. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998; 6: 1153-67.
184. Starovasnik MA, Christinger HW, Wiesmann C, Champe MA, de Vos AM, Skelton NJ. Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states. J Mol Biol 1999; 293: 531-44
185. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997; 91: 695-704.
186. Christinger HW, Fuh G, de Vos AM, Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem 2004; 279: 10382-8.
187. McTigue MA, Wickersham JA, Pinko C, Showalter RE, Parast CV, Tempczyk-Russell A, et al. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis. Structure 1999; 7: 319-30.
188. Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol 2007; 14: 249-50.
189. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996; 271: 5638-46
190. Lee CC, Kreusch A, McMullan D, Ng K, Spraggon G. Crystal structure of the human neuropilin-1 b1 domain. Structure 2003; 11: 99-108.
191. Appleton BA, Wu P, Maloney J, Yin J, Liang WC, Stawicki S, et al. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. Embo J 2007; 26: 4902-12.
192. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci USA 2007; 104: 6152-7.
193. Zachary I. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules. IDrugs 2003; 6: 224-31.
194. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
195. Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 2004; 11: 731-45.
196. Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, et al. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 2004; 64: 3586-92.
197. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-8.
198. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 1369-75.
199. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-70.
200. Quesada AR, Munoz-Chapuli R, Medina MA. Anti-angiogenic drugs: From bench to clinical trials. Med Res Rev 2006; 26: 483-530.
201. Jia H, Jezequel S, Lohr M, Shaikh S, Davis D, Soker S, et al. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Biochem Biophys Res Commun 2001; 283: 164-73.
202. Bainbridge JW, Jia H, Bagherzadeh A, Selwood D, Ali RR, Zachary I. A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. Biochem Biophys Res Commun 2003; 302: 793-9.
203. Cheng L, Jia H, Lohr M, Bagherzadeh A, Holmes DI, Selwood D, et al. Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production. J Biol Chem 2004; 279: 30654-61.
204. Jia H, Bagherzadeh A, Hartzoulakis B, Jarvis A, Lohr M, Shaikh S, et al. Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling. J Biol Chem 2006; 281: 13493-502.
205. Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001; 7: 1249-53.
206. Giordano RJ, Anobom CD, Cardo-Vila M, Kalil J, Valente AP, Pasqualini R, et al. Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. Chem Biol 2005; 12: 1075-83.
207. Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J 2000; 19: 1525-33.
208. Perret GY, Starzec A, Hauet N, Vergote J, Le Pecheur M, Vassy R, et al. In vitro evaluation and biodistribution of a 99mTc-labeled anti-VEGF peptide targeting neuropilin-1. Nucl Med Biol 2004; 31: 575-81.
209. Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crepin M, et al. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci 2006; 79: 2370-81.
210. Starzec A, Ladam P, Vassy R, Badache S, Bouchemal N, Navaza A, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides 2007; 28: 2397-402.
211. Bae DG, Kim TD, Li G, Yoon WH, Chae CB. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin Cancer Res 2005; 11: 2651-61.
212. von Wronski MA, Raju N, Pillai R, Bogdan NJ, Marinelli ER, Nanjappan P, et al. Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. J Biol Chem 2006; 281: 5702-10.
213. Qin X, Wan Y, Li M, Xue X, Wu S, Zhang C, et al. Identification of a novel peptide ligand of human vascular endothelia growth factor receptor 3 for targeted tumour diagnosis and therapy. J Biochem 2007; 142: 79-85.
214. Shrivastava A, von Wronski MA, Sato AK, Dransfield DT, Sexton D, Bogdan N, et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel 2005; 18: 417-24.
215. Goncalves V, Gautier B, Coric P, Bouaziz S, Lenoir C, Garbay C, et al. Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor. J Med Chem 2007; 50: 5135-46.
216. Goncalves V, Gautier B, Garbay C, Vidal M, Inguimbert N. Structure-based design of a bicyclic peptide antagonist of the vascular endothelial growth factor receptors. J Pept Sci 2008; 14: 767-72.
217. Taylor AP, Goldenberg DM. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 2007; 6: 524-31.
218. Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T. A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. J Am Chem Soc 2008; 130: 5744-52.
219. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996; 2: 1371-5.
220. D'Andrea LD, Iaccarino G, Fattorusso R, Sorriento D, Carannante C, Capasso D, et al. Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc Natl Acad Sci USA 2005; 102: 14215-20.
221. Dudar GK, D'Andrea LD, Di Stasi R, Pedone C, Wallace JL. A Vascular Endothelial Growth Factor Mimetic Accelerates Gastric Ulcer Healing in an iNOS-Dependent Manner. Am J Physiol Gastrointest Liver Physiol 2008.
222. Waslif J. Angiogenesis Inhibitors and Stimulators:tHe Emergence of a New Market 2004.
223. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86.
224. Jacobs J. Combating cardiovascular disease with angiogenic therapy. Drug Discov Today 2007; 12: 1040-5.
225. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
226. Featherstone J, Griffiths S. From the analyst's couch. Drugs that target angiogenesis. Nat Rev Drug Discov 2002; 1: 413-4.
227. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 2002; 1: 415-26.
228. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-64.
229. Choe YS, Lee KH. Targeted in vivo imaging of angiogenesis: Present status and perspectives. Curr Pharm Des 2007; 13: 17-31.
230. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007; 58: 491-504.
231. Million RP. Therapeutic area crossroads:aNti-angiogenesis. Nature Rev. Drug Discov. 2008; 7: 115-116.
232. Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2003; 2: 863-71.
233. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437: 497-504.
234. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10: 1095-103.
235. Molin D, Post MJ. Therapeutic angiogenesis in the heart: Protect and serve. Curr Opin Pharmacol 2007; 7: 158-63.
236. Emanueli C, Madeddu P. Changing the logic of therapeutic angiogenesis for ischemic disease. Trends Mol Med 2005; 11: 207-16.
237. Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 2002; 277: 43137-42.
238. Zilberberg L, Shinkaruk S, Lequin O, Rousseau B, Hagedorn M, Costa F, et al. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem 2003; 278: 35564-73.
239. El-Mousawi M, Tchistiakova L, Yurchenko L, Pietrzynski G, Moreno M, Stanimirovic D, et al. A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library. J Biol Chem 2003; 278: 46681-91.
240. An P, Lei H, Zhang J, Song S, He L, Jin G, et al. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Cancer 2004; 111: 165-73.